Login to Your Account



Fibrosis, Genotype 1 Null Responders

Medivir, Gilead Oral Drug Pair Strong in HCV, Early Phase IIa

By Randy Osborne
Staff Writer

Tuesday, March 5, 2013

Their oral combo drug's 100 percent success rate in hepatitis C virus (HCV) patients with liver fibrosis did not do much for shares of Medivir AB and partner Gilead Sciences Inc., probably because the positive interim results from the Phase IIa trial were "baked in" by investors, who must wait to find out more.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription